• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CD56 expression predicts response to Daratumumab-based regimens.

作者信息

Robinette Allen J, Huric Laila, Dona Kameron, Benson Don, Cottini Francesca

机构信息

The Ohio State University, Columbus, OH, USA.

出版信息

Blood Cancer J. 2024 Apr 12;14(1):62. doi: 10.1038/s41408-024-01051-5.

DOI:10.1038/s41408-024-01051-5
PMID:38609355
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11014999/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/762d/11014999/83f5826f7447/41408_2024_1051_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/762d/11014999/1ecd2f63f671/41408_2024_1051_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/762d/11014999/83f5826f7447/41408_2024_1051_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/762d/11014999/1ecd2f63f671/41408_2024_1051_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/762d/11014999/83f5826f7447/41408_2024_1051_Fig2_HTML.jpg

相似文献

1
CD56 expression predicts response to Daratumumab-based regimens.CD56表达可预测基于达雷妥尤单抗方案的疗效。
Blood Cancer J. 2024 Apr 12;14(1):62. doi: 10.1038/s41408-024-01051-5.
2
Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.新型单克隆抗体治疗复发/难治性多发性骨髓瘤疗效与安全性的系统评价和荟萃分析
Oncotarget. 2017 May 16;8(20):34001-34017. doi: 10.18632/oncotarget.16987.
3
Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials.达雷妥尤单抗治疗复发/难治性多发性骨髓瘤的疗效和安全性：一项随机对照试验的荟萃分析。
Medicine (Baltimore). 2023 Sep 22;102(38):e35319. doi: 10.1097/MD.0000000000035319.
4
Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.达雷妥尤单抗单药治疗与来自捷克共和国的真实世界历史对照数据在接受过大量治疗且高度难治的多发性骨髓瘤患者中的校正比较。
Curr Med Res Opin. 2018 May;34(5):775-783. doi: 10.1080/03007995.2017.1410121. Epub 2018 Feb 15.
5
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.监测接受达雷妥尤单抗治疗的多发性骨髓瘤患者：揭示单克隆抗体干扰。
Clin Chem Lab Med. 2016 Jun 1;54(6):1095-104. doi: 10.1515/cclm-2015-1031.
6
Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.在接受达雷妥尤单抗治疗的患者中，单核细胞和粒细胞降低骨髓瘤细胞上 CD38 的表达水平。
Clin Cancer Res. 2017 Dec 15;23(24):7498-7511. doi: 10.1158/1078-0432.CCR-17-2027. Epub 2017 Oct 12.
7
Daratumumab for the Treatment of Multiple Myeloma: A Review of Clinical Applicability and Operational Considerations.达雷妥尤单抗治疗多发性骨髓瘤：临床适用性和操作注意事项的综述。
Ann Pharmacother. 2022 Aug;56(8):927-940. doi: 10.1177/10600280211058754. Epub 2021 Dec 28.
8
Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis.达雷妥尤单抗治疗多发性骨髓瘤的疗效和安全性：系统评价和荟萃分析。
J Int Med Res. 2021 Aug;49(8):3000605211038135. doi: 10.1177/03000605211038135.
9
[The Effecacy and Safety of Daratumumab Based Regimens in Relapsed/Refractory Multiple Myeloma: A Single-Center Real-World Data Analysis].[达雷妥尤单抗方案治疗复发/难治性多发性骨髓瘤的疗效与安全性：单中心真实世界数据分析]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024 Jun;32(3):763-767. doi: 10.19746/j.cnki.issn.1009-2137.2024.03.016.
10
Should all newly diagnosed MM patients receive CD38 antibody-based treatment?所有新诊断的多发性骨髓瘤患者都应该接受基于 CD38 抗体的治疗吗？
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):259-263. doi: 10.1182/hematology.2020000161.

引用本文的文献

1
CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies.CD200免疫检查点表达与接受抗CD38单克隆抗体治疗的多发性骨髓瘤患者的较差预后相关。
Oncoimmunology. 2025 Dec;14(1):2532226. doi: 10.1080/2162402X.2025.2532226. Epub 2025 Jul 20.
2
CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma.CD56表达调节NAD+代谢格局并预测多发性骨髓瘤对抗CD38疗法的敏感性。
Blood Cancer J. 2025 May 2;15(1):83. doi: 10.1038/s41408-025-01284-y.
3
CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma.

本文引用的文献

1
EZH2 targeting induces CD38 upregulation and response to anti-CD38 immunotherapies in multiple myeloma.靶向EZH2可诱导多发性骨髓瘤中CD38上调并增强对抗CD38免疫疗法的反应。
Leukemia. 2023 Sep;37(9):1925-1928. doi: 10.1038/s41375-023-01983-0. Epub 2023 Aug 2.
2
Multiomic Mapping of Acquired Chromosome 1 Copy-Number and Structural Variants to Identify Therapeutic Vulnerabilities in Multiple Myeloma.获得性1号染色体拷贝数和结构变异的多组学图谱分析以鉴定多发性骨髓瘤的治疗弱点
Clin Cancer Res. 2023 Oct 2;29(19):3901-3913. doi: 10.1158/1078-0432.CCR-22-3209.
3
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA.
CREB1 促进免疫检查点 HLA-E 的表达，导致多发性骨髓瘤中的免疫逃逸。
Leukemia. 2024 Aug;38(8):1777-1786. doi: 10.1038/s41375-024-02303-w. Epub 2024 Jun 20.
isatuximab治疗的复发/难治性多发性骨髓瘤患者按1q21+状态划分的主要结局：来自ICARIA-MM和IKEMA的亚组分析
Haematologica. 2022 Oct 1;107(10):2485-2491. doi: 10.3324/haematol.2022.280660.
4
Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma.重新定义 CD56 在多发性骨髓瘤中的生物标志物和治疗靶点。
Mol Cancer Res. 2022 Jul 6;20(7):1083-1095. doi: 10.1158/1541-7786.MCR-21-0828.
5
Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma.系统医学剖析 chr1q-amp 揭示了多发性骨髓瘤靶向治疗的新 PBX1-FOXM1 轴。
Blood. 2022 Mar 31;139(13):1939-1953. doi: 10.1182/blood.2021014391.
6
Myeloma cells induce the accumulation of activated CD94low NK cells by cell-to-cell contacts involving CD56 molecules.骨髓瘤细胞通过涉及CD56分子的细胞间接触诱导活化的CD94低表达自然杀伤细胞的积累。
Blood Adv. 2020 May 26;4(10):2297-2307. doi: 10.1182/bloodadvances.2019000953.
7
IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.来那度胺可通过使 Ikaros 和 Aiolos 缺失从而诱导多发性骨髓瘤细胞对达妥木单抗介导的细胞毒性作用敏感。
Blood. 2018 Nov 15;132(20):2166-2178. doi: 10.1182/blood-2018-05-850727. Epub 2018 Sep 18.
8
CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade.CD38 介导的免疫抑制作为肿瘤细胞逃避 PD-1/PD-L1 阻断的机制。
Cancer Discov. 2018 Sep;8(9):1156-1175. doi: 10.1158/2159-8290.CD-17-1033. Epub 2018 Jul 16.
9
CD38 antibodies in multiple myeloma: back to the future.多发性骨髓瘤中的 CD38 抗体：回到未来。
Blood. 2018 Jan 4;131(1):13-29. doi: 10.1182/blood-2017-06-740944. Epub 2017 Nov 8.
10
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma.CD38 表达和补体抑制剂影响多发性骨髓瘤患者对达雷妥尤单抗治疗的反应和耐药性。
Blood. 2016 Aug 18;128(7):959-70. doi: 10.1182/blood-2016-03-703439. Epub 2016 Jun 15.